Form 4: Amicus CFO Sells FOLD Shares Under 10b5-1 Plan

Amicus Therapeutics' CFO, Simon N.R. Harford, reported the disposition of 71,303 common shares at $14.25 each, executed under a Rule 10b5-1 plan.

Summary

• Simon N.R. Harford, Chief Financial Officer of Amicus Therapeutics, Inc. (FOLD), reported a transaction involving the company's common stock.
• On December 26, 2025, Harford disposed of 71,303 shares of Amicus Therapeutics common stock.
• The shares were sold at a price of $14.25 per share.
• Following this transaction, Harford beneficially owns 143,595 shares of Amicus Therapeutics common stock directly.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating it was pre-arranged.

Sentiment

Score: 5

Explanation: The transaction is a disposition of shares by a CFO, which is typically viewed neutrally given it was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not based on new, immediate insider information.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, which suggests the sale was pre-scheduled and not based on immediate, non-public insider information.

Negatives

• A disposition of 71,303 shares by a key executive, even if pre-planned, represents a reduction in insider ownership and could be perceived negatively by some investors.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Simon N.R. Harford, Chief Financial Officer, disposed of 71,303 shares of common stock at $14.25 per share on December 26, 2025, under a Rule 10b5-1(c) plan.

Stakeholder Impact

• Shareholders: May interpret the CFO's share disposition differently; some might see it as a routine tax-related sale or portfolio diversification, while others might view it as a lack of confidence, despite the 10b5-1 plan.

Key Dates

Recommendation

The disposition of shares by the CFO, while significant, was executed under a Rule 10b5-1(c) plan. This suggests the sale was pre-scheduled for reasons such as tax planning or portfolio diversification, rather than being based on new, non-public information. While insider sales can sometimes raise concerns, the pre-arranged nature of this transaction typically leads to a more neutral interpretation. Investors should consider this transaction in the broader context of the company's financial performance and strategic outlook.

Keywords

Amicus Therapeutics, FOLD, Insider Transaction, Form 4, CFO, Stock Sale, 10b5-1 Plan, Simon Harford